Avid Bioservices, Inc. (NASDAQ:CDMO – Get Rating) Director Richard B. Hancock sold 5,000 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $16.59, for a total value of $82,950.00. Following the transaction, the director now owns 39,134 shares of the company’s stock, valued at $649,233.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Avid Bioservices Stock Performance
NASDAQ:CDMO opened at $17.11 on Monday. The stock has a market cap of $1.07 billion, a P/E ratio of 10.12 and a beta of 1.76. The stock has a 50 day simple moving average of $15.82 and a 200 day simple moving average of $16.11. The company has a current ratio of 1.77, a quick ratio of 1.30 and a debt-to-equity ratio of 0.78. Avid Bioservices, Inc. has a 1-year low of $11.30 and a 1-year high of $22.38.
Avid Bioservices (NASDAQ:CDMO – Get Rating) last released its quarterly earnings results on Tuesday, December 6th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $34.76 million during the quarter, compared to analysts’ expectations of $31.00 million. Avid Bioservices had a return on equity of 3.29% and a net margin of 88.13%. Research analysts anticipate that Avid Bioservices, Inc. will post 0.01 earnings per share for the current year.
Institutional Trading of Avid Bioservices
Analyst Ratings Changes
Several research analysts recently commented on the company. Stephens reduced their price target on Avid Bioservices to $22.00 in a research report on Monday, December 12th. Craig Hallum reduced their price target on Avid Bioservices from $30.00 to $25.00 in a research report on Wednesday, December 7th. StockNews.com raised Avid Bioservices to a “sell” rating in a research report on Wednesday, December 7th. Finally, Royal Bank of Canada cut their price objective on Avid Bioservices from $22.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, December 7th.
Avid Bioservices Company Profile
Avid Bioservices, Inc engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support.
- Get a free copy of the StockNews.com research report on Avid Bioservices (CDMO)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.